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Background. Experimental studies in animals suggest that apolipoprotein (apo) C-I is an important regulator of triglycerides in
fasting and postprandial conditions and associated with carotid atherosclerosis. Methods. A cross-sectional study was conducted
with 81 subjects, aged 56–80 years recruited from a population health survey. The participants underwent a fat tolerance test (1g
fat per Kg body weight) and carotid atherosclerosis was determined by ultrasound examination. VLDL particles, Sf 20–400, were
isolated and their lipid composition and apoC-I content determined. Results. The carotid plaque area increased linearly with the
numberofapoC-ImoleculesperVLDLparticles(P = 0.048)underfastingconditions.Fastingtriglycerides increasedacrosstertiles
of apoC-I per VLDL particle in analysesadjusted for apoC-II and -C-III, apoE genotype and traditional cardiovascular risk factors
(P = 0.011). The relation between apoC-I in VLDL and serum triglycerides was conveyed by triglyceride enrichment of VLDL
particles (P for trend <0.001.The amount of apoC-I molecules per VLDL was correlated with the total (r = 0.41, P<0.0001) and
incremental (r = 0.35, P<0.001) area under the postprandial triglyceride curve. Conclusions. Our ﬁndings support the concept
that the content of apoC-I per VLDL particle is an important regulator of triglyceride metabolism in the fasting and postprandial
state and associated with carotid athrosclerosis.
1.Introduction
Growing evidence, based on genetically engineered mice
models and a polymorphism in the promoter region of
apoC-I in humans (HpaI) associated with increased expres-
sion of apoC-I transcription, supports the concept that
apoC-I plays a pivotal role for regulation of triglycerides
in fasting and postprandial conditions. The presence of the
apoC-I gene is shown to increase fasting and postprandial
triglycerides compared to apoC-deﬁcient mice independent
of the apoE gene status [1] and the apoC-III gene status
[2]. Likewise, overexpression of the human apoC-I gene in
mice (APOC1) promotes elevated triglyceride levels, mostly
attributed to increased levels of very-low-density lipopro-
teins (VLDLs) [3, 4]. Furthermore, the presence of the
HpaI polymorphism in humans is associated with increased
triglyceride levels [5, 6]. Experimental studies have shown
that ApoC-I modulates lipid metabolism by increasing
the production rate of hepatic VLDLs [1], inhibition of
lipoprotein lipase activity [1, 7, 8], interference with the
apoE-mediated uptake of VLDLs [5, 9], and inhibition of
cholesteryl ester transfer protein (CETP) [10, 11].
ApoC-Iisprimarily expressedintheliver[12]andsecr et-
edintoplasmaasa6.6kDaproteinwhere60–70%isassociat-
ed with high-density lipoprotein (HDL) and 30–40% associ-
ated with VLDL under fasting conditions [13]. Total plasma2 Journal of Lipids
levels of apoC-I are increased in patients with hypertriglyc-
eridemia [13, 14] and decreased in patients with Tangier’s
disease [15]. During postprandial elevation of triglyceride-
rich lipoproteins (TRLs), apoC-I is transferred from HDL to
VLDL (Svedberg ﬂotation (Sf) 20–400) [16]w i t h o u ta ﬀect-
ing total plasma levels of apoC-I [17].
Data from clinical studies suggest that the content of
apoC-I molecules per VLDL particle in the fasting [18]a n d
postprandial state [19, 20] is a novel risk factor for athero-
sclerosis andcoronary artery diseases (CAD).VLDLparticles
are enriched with apoC-I in patients with CAD [19], in
healthy individuals with increased intima-media thickness
(IMT) [21] and are an independent predictor for IMT [20]
and the size of carotid atheroscleroticplaques[18]. However,
the impact of phenotypic expression of apoC-I in VLDLs on
lipid metabolism under fasting and postprandial conditions
is not known. To address this question, we determined
the content of apoC-I per VLDL molecule and related
them to serum lipids and LPL activity in the fasting and
postprandial conditions amongs u b j e c t sw i t ha n dw i t h o u t
carotid atherosclerosis recruited from a general population.
2.Materialsand Methods
2.1. Study Participants. The participants of the study were
recruited from a population health study (the ﬁfth survey of
theTromsøstudyin2001),whichincludedultrasoundexam-
ination of the right carotid artery. Persons aged 56–80 years
old were eligible for the plaque group of the present study
if they had at least one plaque with a thickness of ≥2.5mm
in the carotid bifurcation or internal carotid artery, and for
the plaque-free group if they had no plaques in the carotid
arteries. Persons who responded positive to our invitation
letter were invited to a screening visit. At the screening
visit, a complete medical history, physical examination,
and blood samples were taken with special emphasis on
exclusioncriteria.Exclusioncriteriawereanyofthefollowing
conditions; regular use of lipid-lowering drugs (HMG-CoA
reductase inhibitors, resins, or nicotinic acid derivates) or
oral anticoagulants, cancer, or other serious life-threatening
medical conditions, hypothyroidism, renal, hepatic, or psy-
chiatric disease, and current abuse of alcohol or drugs.
Adetailedinterviewontheoccurrenceofcerebrovascular
and cardiovascular events, deﬁned as prior or present tran-
sient ischemic attacks (TIAs), stroke, amaurosis fugax, an-
gina pectoris, myocardial infarction, peripheral vascular
disease, and diabetes, and smoking habits and drugs was
obtained. Hypertension was deﬁned as usage of antihyper-
tensive medication or systolic pressure above 160mmHg
and/or diastolic pressure above 95mmHg. Diabetes was self-
reported or deﬁned as fasting plasma glucose ≥7.0mmol/L
or non-fasting ≥11.1mmol/L at two occasions. Height and
weight were measured with the participants in light clothing
without shoes; body mass index (BMI) was calculated as
weight per height squared (kg/m2). Blood pressure was
recorded in seated position by the use of an automatic device
(DinamapVital SignsMonitor).Three recordings were made
at 1-minute intervals, and the mean of the last two values is
used in this report. Eligible persons were invited to a second
visit, where ultrasound examination of both carotid arteries
was performed, and the participants were subjected to a
fat tolerance test. Eight of the eligible subjects had diabetes
mellitus type II. None of these had medical treatment, but
receivedadviceondietaryrestrictionsonly.Informedwritten
consent was obtained from the participants, and the regional
committee for medical research ethics approved the study.
The study was performed at the Clinical Research Unit at the
University Hospital of North Norway.
2.2. Ultrasound Examination. At the population health
screening, high-resolution B-mode and color Doppler/
pulsed-wave Doppler ultrasonography of the right carotid
artery was performed as described previously [22, 23].
Assessment of plaque size and morphology was made in all
plaques present in the near and far walls of the common
carotid, the bifurcation, and the internal carotid arteries on
both sides (12 locations). All examinations and measure-
ments of all plaques were recorded on videotapes. Stored
B-mode images were subsequently transferred to a personal
computeranddigitizedintoframesof768×576pixelsof256
grey levels each (0 = black and 256 = white) with the use of a
commerciallyavailablevideograbbercard(meteorII/Matrox
Intellicam). Measurements of plaque area were made with
the use of the Adobe Photoshop image-processing program
(version 7.0.1), by tracing the perimeter of each plaque.
2.3. Fat Tolerance Test. A fat-tolerance test was conducted
using a test meal prepared from standard porridge cream
containing 70% of calories from fat of which 66% saturated
fat, 32% monounsaturated fat, and 2% polyunsaturated fat.
The test meals were served with two teaspoons of sugar,
cinnamon, and two glasses (150mL each) of sugar-free
juice. The test meals were freshly prepared each morning.
A weight-adjusted meal (1 gram fat per kg body weight)
was served at 8:00a.m. and consumed over a 15-min period.
The participants were allowed to drink 350mL calorie-free
beverages and eat an apple during the following 8hrs.
2.4. Blood Collection, Isolation of Triglyceride-Rich Lipopro-
teins and Storage. Blood was drawn from an antecubital
vein in the morning at 7:45a.m, after 12 hours overnight
fasting and 48hrs refrain of exhaustive physical exercise and
a l c o h o lc o n s u m p t i o n ,a n dt h e n ,2 ,4 ,6 ,a n d8h o u r sa f t e r
the meal, using a 19-gauge needle in a vacutainer system
with minimal stasis. Serum was prepared by clotting whole
blood in a glass tube at room temperature for 1 hour and
then centrifuged at 2000g for 15 minutes at 22◦C. Aliquots
of 1mL were transferred into sterile cryovials (Greiner
labortechnik, N¨ urtringen, Germany), ﬂushed with nitrogen,
and frozen at −70◦C until further analysis.
VLDL was isolated by preparative ultracentrifugation in
the fasting state and four hrs after ingestion of the standard
high-fat meal (postprandial state). First, chylomicrons (CM)
were removed from plasma by over layering 8mL EDTA
plasma with 5mL of NaCl solution (density 1.006kg/L NaCl
solution with 0.02% sodium azide and 0.01% EDTA) inJournal of Lipids 3
a cellulose nitrate tube (Beckman Instruments Inc., Calif,
USA) and centrifuged in a Beckman SW40Ti swinging-
bucket rotor at 20.000rpm for 1hr at 4◦C. The CM, with Sf
rates >400, was removed by aspiration. Second, plasma
samples were relayered with 5mL 1.006kg/L NaCl solution
and subjected to centrifugation at 40.000rpm for 20hrs
at 20◦C. VLDL, with Sf 20–400, was carefully removed
by aspiration from the top of the tube. ApoB-48 was
measured in random samples and revealed that the VLDL
fractions contained substantially less than 10% apoB-48
mass compared to total apoB mass in both the fasting and
postprandial states, implying that 5–15% of apoC-I within
the VLDL fraction can be due to remaining chylomicron
remnants [21]. VLDL fractions were divided into three
aliquots in cryovials, ﬂushed with nitrogen, and frozen at
−70◦C until further analysis.
2.5. Serum Lipids and Apolipoproteins Measurements. Serum
lipidswereanalyzedonaCobasMiraS(RocheDiagnostics,F.
Hoﬀmann-La Roche Ltd., Basel, Switzerland) with reagents
from ABX Diagnostics (Montpellier, France). Total choles-
terol (CHOD-PAP) and triglycerides (GPO-PAP) were mea-
sured with enzymatic colorimetric methods. Low-density
lipoprotein (LDL) and high-density lipoprotein cholesterol
were measured by selective inhibition colorimetric assays
(LDL cholesterol direct and HDL cholesterol direct, respec-
tively,ABXDiagnostics). SerumapolipoproteinA-I(apoA-I)
and apolipoprotein B (apoB) were analyzed by turbidimetry
onCobasMiraSwithreagentsfromABXDiagnostics.Serum
apolipoprotein E (apoE) was measured by an enzyme-linked
immunosorbent assay, Apo-Tek ApoE (PerImmune Inc.,
Rockville,Md,USA),andgenotypingofapoEwasperformed
according to Hixson and Vernier [24] with slight modiﬁ-
cations. An enzymatic immunoassay was used to measure
apoC-I in isolated VLDL fractions [25]. Apolipoprotein CII
in serum was analyzed by turbidimetry with reagents from
Kamiy Biomed Comp (Seattle, WA, USA). ApoC-I in serum
(AssayMax Human Apolipoprotein C-I ELISA kit), and
apoC-III (AssayMax Human Apolipoprotein C-III ELISA
kit) in serum, and isolated VLDL fractions were measured
by commercial available immunoassays according to the
manufacturer’s descriptions(AssayproLLC,St.Charles, MO,
USA).
2.6. Lipoprotein Lipase Measurements. Eight hours after in-
gestion of the test meal, blood was drawn into vacutainers
(Becton Dickinson, Meylan, Cedex, France) containing
heparin as anticoagulant, and the heparinized blood was
immediately placed on ice. Unfractionated heparin was
given as a bolus injection (100IU/kg bodyweight) on the
contralateral arm to mobilize LPL from the endothelial
surface into the circulation. A second blood sample was
obtained exactly 15 minutes after heparin administration
and immediately placed on ice. Heparinized plasma was
recovered within 30 minutes by centrifugation (2000×gf o r
10min) at 4◦C, divided into aliquots of 1.0mL in cryovials,
ﬂushed with nitrogen, and frozen at −70◦Cu n t i lf u r t h e r
analysis. LPL activity wasdeterminedaspreviouslydescribed
[26, 27]. In short, 185μL sonicated emulsion of 3H-oleic
acid-labelled triolein in 10% Intralipid (Fresenius Kabi) was
used as substrate and incubated with 15μL heparinized
plasma samples. Plasma samples were preincubated for
2hrs on ice with 0.5vol goat antibodies to hepatic lipase
(HL) to suppress HL activity. LPL activity was expressed as
mU/mL corresponding to nmol of fatty acid released per
minute at 25◦C[ 28]. LPL mass was measured in postheparin
plasma with a commercial ELISA kit (MARKIT-M LPL
ELISA, Dainippon Sumitomo Pharma Co., Ltd., Osaka,
Japan) according to manufacturer’s instructions. Preheparin
plasma samples had the following values for the total study
population: LPL activity 0.97 ± 0.37mU/mL, LPL mass
83.6 ± 36.9ng/mL, and speciﬁc activity 0.02 ± 0.02mU/ng.
Postheparin plasma samples had the following values for the
total study population: LPL activity 138.4 ± 43.1mU/mL,
LPL mass 729.1 ± 293.7ng/mL, and speciﬁc activity 0.20 ±
0.06mU/ng.
2.7. Calculations and Statistics. The number of apoC-I per
VLDL particle and apoC-III per VLDL particle were calcu-
lated by dividing apolipoprotein concentrations in density
fraction Sf20–400 by their respective molecular mass (apoB-
100 = 549kD, apoC-I = 6.6kD, and apoC-III = 8.8kD). The
fraction molarity of apoC-I/apoC-III was then divided by
the corresponding molarity of apoB. Continuous variables
were tested for normal distribution, and logarithmically
transformed in statistical analyses if not normally dis-
tributed. Diﬀerences in continuous variables from fasting to
postprandial conditions were analyzed by paired t-test. The
number ofapoC-I particles perVLDL was divided in tertiles,
and signiﬁcance of linear trends across tertiles was tested by
linear regression. Pearson’s correlation coeﬃcientswere used
to examine correlations between continuous variables. All
analyses were performed using SPSS (SPSS Inc., Chicago, Ill,
USA)forwindowssoftware, version16.0.Two-sided P values
(<0.05) were considered statistically signiﬁcant. Results are
expressed as means ± 1SD unless otherwise stated.
3.Results
Plasma VLDL particles, Sf 20–400, were isolated from all
study participants by preparative ultracentrifugation before
(fasting condition) and 4hrs after (postprandial condition)
intake of a standard high-fat meal and analyzed for triglyc-
erides, total cholesterol, and apolipoproteins B, C-I, and C-
III.
Characteristics, traditional cardiovascular risk factors,
the presence of carotid plaques, diabetes mellitus and car-
diovascular diseases, and regular use of major cardiovascular
drugs across tertiles of the number of apoC-I per VLDL
particle under fasting conditions are shown in Table 1.
Fasting triglycerides increased signiﬁcantly across tertiles of
apoC-I per VLDL particle in unadjusted analysis (P = 0.01)
and after adjustment for age, gender, BMI, apoC-II, apoC-
III, and apoE genotype (P = 0.012). Further adjustments
for cardiovascular risk factors such as smoking, blood pres-
sure, and serum lipids and apolipoproteins did not aﬀect4 Journal of Lipids
Table 1: Characteristics of study participants. Characteristics of subjects included in the study across tertiles of apoC-I molecules per VLDL
particles (n = 81) under fasting conditions. Values are means ± 1SD or percentage with number in brackets.
Variables ApoC-I per VLDL P for trend
T1 T2 T3
Apo-CI per VLDL 3.5 ±1.16 .2 ± 0.91 2 .8 ±3.1
Men (%) 56 (15) 56 (15) 56 (15) 1.00
Age (yrs) 68.1 ±5.56 9 .3 ± 6.77 0 .4 ±6.60 . 1 9
Smoking(%) 19 (5) 22 (6) 22 (6) 0.68
Body mass index (kg/m2)2 6 .8 ±3.92 6 .1 ± 3.82 6 .7 ±3.90 . 9 3
Systolic blood pressure (mmHg) 127 ±17 130 ± 17 132 ±20 0.30
Diastolic blood pressure (mmHg) 74 ±97 5 ± 11 73 ±9 0.91
Total cholesterol (mmol/L) 6.27 ±1.22 5.68 ± 1.63 6.26 ±0.98 0.98
HDL cholesterol (mmol/L) 1.87 ±0.53 1.76 ± 0.44 1.67 ±0.46 0.13
LDL cholesterol (mmol/L) 3.89 ±0.91 4.02 ± 1.11 3.97 ±0.85 0.76
Triglycerides (mmol/L) 0.90 ±0.36 1.25 ± 0.67 1.35 ±0.77 0.01
Apolipoprotein A1 (g/L) 1.45 ±0.27 1.42 ± 0.23 1.40 ±0.22 0.47
Apolipoprotein B (g/L) 1.06 ±0.20 1.07 ± 0.23 1.11 ±0.18 0.44
Apolipoprotein C-I (mg/L) 206.7 ±59.0 205.5 ± 65.9 215.7 ±76.10 . 6 6
Apolipoprotein C-II (mg/L) 34.4 ±10.54 0 .1 ± 15.34 4 .8 ±19.1 0.015
Apolipoprotein C-III (mg/L) 107.2 ±40.6 109.2 ± 39.7 130.8 ±45.40 . 1 2
Apolipoprotein E (mg/L) 42.1 ±12.54 0 .4 ± 15.04 6 .1 ±17.40 . 3 4
Hypertension (%) 33 (9) 30 (8) 56 (15) 0.16
Diabetes (%) 4 (1) 19 (5) 7 (2) 0.65
Coronary artery disease (%) 19 (5) 4 (1) 30 (8) 0.29
Cerebrovascular events (%) 11 (3) 0 (0) 7 (2) 0.58
Antihypertensive drugs (%) 15 (4) 4 (1) 22 (6) 0.37
Platelet inhibitors (%) 15 (4) 11 (3) 19 (5) 0.62
Omega-3 FA supplementation (%) 52 (14) 44 (12) 56 (15) 0.79
Carotid plaques (%) 30 (8) 63 (17) 63 (17) 0.016
Plaque area (mm2)4 .0 ±2.44 .4 ± 2.78 .8 ±4.3 0.048
the relationship. Total serum levels of apolipoprotein C-II
(P = 0.015) and apoC-III (P = 0.12) increased with apoC-I
enrichment of VLDL particles. Neither other cardiovascular
risk factors such as age, gender, smoking, BMI, blood
pressure, serum lipids and apolipoproteins, hypertension
a n dd i a b e t e sm e l l i t u s ,n o rc a r d i o v a s c u l a rd i s e a s e sa n dd r u g s
were associated with tertiles of apoC-I per VLDL particle.
The distribution of apoE genotypes in our study population
was 58% with the E3/3 isoform, 30% E3/4, 10% E2/3, 1%
E4/4, 1% E2/4, and none had the E2/2 isoform.
The proportion of subjects with carotid plaques (P =
0.016) and total carotid plaque area (P = 0.048) increased
signiﬁcantly with the number of apoC-I per VLDL particle
(Table1).These trends remained signiﬁcant after adjustment
for age, gender, BMI, apoC-II, apoC-III, and apoE genotype
(P = 0.011 and P = 0.043 for proportion of carotid plaques
andplaquearea, resp.). Furtheradjustments for cardiovascu-
lar risk factors as smoking, blood pressure, and serum lipids
and apolipoproteins did not aﬀect the relationship.
The composition of VLDL particles with increasing en-
richment of apoC-I per VLDL particle under fasting condi-
tions are shown in Table 2.E v e nt h o u g hn oa s s o c i a t i o nw a s
found between the amount of VLDL particles, assessed by
the concentration of apoB within the VLDL fraction and
their enrichment with apoC-I, linear regression analysis
showed a marked increase in the content of triglycerides
(P<0.001)and modestincrease in thecontentofcholesterol
(P<0.001) in VLDL particles with increasing enrichment of
apoC-I. The relation between VLDL content of apoC-I and
triglycerides remained signiﬁcant even after adjustment for
age, BMI, the content of apoC-III per VLDL particle, and
apoE genotype (Table 2).
We wanted to further investigate if the increased content
of triglycerides in VLDL particles enriched with apoC-I
was associated with less eﬃcient hydrolysis promoted by
LPL. The functional pool of LPL is anchored to heparan
sulphate proteoglycans (HSPGs) at the endothelial surface,
and only trace amounts are available in the circulation
[29]. Unfractionated heparin has higher aﬃnity for LPL
than heparan sulphate, and heparin infusion will, therefore,
displaceLPL from theendothelialsurface intothecirculation
[27]. Measurement of functional activity and mass of LPL in
postheparin plasma is therefore assumed to reﬂect the func-
tionandbioavailability,respectively,ofLPLattheendothelial
surface [27]. Simple correlation analysis revealed an inverse
correlation between the amount of apoC-I molecules perJournal of Lipids 5
Table 2: Composition of VLDL particles. Composition of VLDL particles across tertiles of the number of apoC-I per VLDL particle isolated
under fasting conditions and 4hrs after intake of a standard high-fat meal (Postprandial conditions) (n = 81). Values are means ± 1SD .
Fasting conditions (0hrs) ApoC-I per VLDL P for trend
T1 T2 T3
Apo-CI per VLDL 3.5 ± 1.16 .2 ±0.91 2 .8 ±3.1
ApoB (mg/L) 43.7 ± 19.24 7 .3 ±25.84 3 .6 ±23.90 . 9 8
Triglycerides (μmol/mg apoB in VLDL)
Crude analysis 6.8 ± 2.71 1 .9 ±5.21 5 .7 ±8.1 <0.001
Adjusted model∗ 6.9 ± 2.71 1 .5 ±4.71 6 .3 ±7.9 <0.001
Total cholesterol (μmol/mgapoB in VLDL)
Crude 4.9 ± 0.85 .8 ±1.36 .8 ±2.4 <0.001
Ajusted model∗ 4.8 ± 0.85 .7 ±1.37 .0 ±2.3 <0.001
Postprandial conditions (4hrs) ApoC-I per VLDL P for trend
T1 T2 T3
Apo-CI per VLDL 5.3 ± 1.81 0 .5 ±1.52 2 .6 ±5.3
ApoB (mg/L) 45.9 ± 23.75 2 .0 ±28.54 4 .3 ±20.20 . 8 1
Triglycerides (μmol/mg apoB in VLDL)
Crude analysis 13.6 ±7.92 0 .7 ±9.82 8 .1 ±13.0 <0.001
Adjusted model∗ 13.1 ±9.81 9 .8 ±8.02 9 .2 ±14.3 0.007
Total cholesterol (μmol/mgapoB in VLDL)
Crude analysis 5.5 ± 1.57 .3 ±2.17 .6 ±2.4 <0.001
Ajusted model∗ 5.4 ± 1.57 .4 ±2.27 .7 ±2.4 0.001
∗model adjusted for age, body mass index, apoE genotype and the number of apoC-III per VLDL particle.
VLDL particle and postheparin LPL activity (r =− 0.31, P =
0.006) which remained signiﬁcant after adjustment for the
amount of apoC-III per VLDL particle (r =− 0.27, P =
0.024)butnosigniﬁcant association toLPL mass(r =− 0.05,
P = 0.65). Postheparin LPL activity decreased signiﬁcantly
across tertiles of VLDL particles enriched with apoC-I (P =
0.01)from152.8±47.4mU/mLinT1to122.6±40.7mU/mL
in T3 under fasting conditions, whereas LPL mass was
unaﬀected by the apoC-I enrichment of VLDL particles
(Figure 1). The relation remained signiﬁcant even after
adjustment for age, BMI, the content of apoC-III per VLDL,
and apoE genotype (P = 0.013).
The number of apoC-I per VLDL particle increased
from 7.5 ± 4.9 under fasting conditions to 12.8 ± 6.8u n d e r
postprandial conditions (4hrs after intake of a standard
high-fat meal) (P<0.0001), and simple correlation analysis
revealed strong associations between the two variables (r =
0.61, P<0.0001) (Figure 2). As seen under fasting condi-
tions, linear regression analysis showed a marked increase
in the content of triglycerides (P<0.001) and modest
increase in the content of cholesterol (P<0.001) in
VLDL particles with increasing enrichment of apoC-I in the
postprandial state (Table 2). The relation between the VLDL
content of apoC-I and triglycerides in the postprandial state
remained signiﬁcant even after adjustment for age, BMI, the
content of apoC-III per VLDL particle, and apoE genotype
(Table 2). Even though the number of VLDL particles
did not increase in the postprandial state, their content
of triglycerides and cholesterol increased from fasting to
postprandial conditions across tertiles of apoC-I enrichment
(Table 2).
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Figure 1: Line graph showing postheparin LPL activity and LPL
mass across tertiles of the number of apoC-I per VLDL particle in
the fasting state. Groups (T1–T3) were deﬁned by their respective
tertiles of the number of apoC-I per VLDL particle. Tertiles of the
number of apoC-I per VLDL particle in the fasting state were as
follows (mean, range): T1 (3.5, 0.5–5.0), T2 (6.2, 5.1–8.1), and T3
(12.8, 8.2–27.2). Values are means ± SEM.
To investigate if enrichment of VLDL particles with
apoC-I aﬀected postprandial lipemia, serum triglycerides
were measured before and every second hour for 8hrs after a
fat tolerance test and correlated to the number of apoC-I per
VLDL particle isolated in the postprandial state (4hrs after
ingestion of the meal). The amount of apoC-I molecules per
VLDL was correlated with the total (r = 0.41, P<0.0001)
and incremental (r = 0.35, P<0.001) area under the curve6 Journal of Lipids
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Figure 2: Dot plots showing the number of apoC-I per VLDL particle for each participant under fasting and postprandial conditions (a),
and the relation between the number of apoC-I per VLDL particle under fasting and postprandial conditions (b).
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Figure 3: Line graphs showing serum concentrations of triglycerides (Tg) over time in groups after intake of a standard high-fat meal (a)
andchanges in area under the curve (AUC) for serum triglycerides in the postprandial state (0–8hrs) across tertiles ofthe number ofapoC-I
per VLDL particle in the postprandial state (b). Groups (T1–T3) were deﬁned by their respective tertiles of the number of apoC-I per VLDL
particle in the postprandial state. Tertiles of the number of apoC-I per VLDL particle inthe postprandialstatewere as follows(mean,range):
T1 (5.3, 1.1–7.9), T2 (10.5, 8.1–13.0), and T3 (22.6, 13.7–40.3). Values are means ± SEM. Linear trend analyses were adjusted for age, BMI,
the content of apoC-III per VLDL particle, and APOE genotyping.
(AUC) of postprandial triglycerides, and the associations
remained signiﬁcant even after adjustment for age, BMI,
the apoC-III molecules per VLDL, and apoE genotype
(data not shown). The total AUC for serum triglycerides
increased signiﬁcantly with apoC-I enrichment of VLDL
particles (P for trend = 0.003 in analyses adjusted for age,
BMI, the content of apoC-III molecules per VLDL, and
apoE genotype) from 8.4 ± 3.6mmol/L∗hi nT 1t o1 3 .0 ±
6.1mmol/L∗hi nT 3( F i g u r e3). Similarly, the incremental
AUC for serum triglycerides increased signiﬁcantly with the
number of apoC-I per VLDL particles (P for trend =0.043
in analyses adjusted for age, BMI, the content of apoC-III
molecules per VLDL, and apoE genotype) from 2.9 ±
1.8mmol/L∗hi nT 1t o4 .6±2.9mmol/L∗hi nT 3( F i g u r e3).
Postheparin LPL activity was inversely correlated with the
total (r =− 0.34, P = 0.002) and incremental (r =− 0.28,
P = 0.01) area under the postprandial triglyceride curve.
4.Discussion
Studies on humans [6, 30]a n dm i c e[ 3, 31]h a v es h o w nt h a t
increased expression of apoC-I promoted combined hyper-
lipidemia with the most pronounced enhancing eﬀect on
plasma triglycerides. Subsequent mechanistic studies haveJournal of Lipids 7
shown that the impact of apoC-I on lipid metabolism was
mainly conﬁned to VLDL metabolism [8]. Thus, it is per-
tinent to focus on the impact of phenotypic expression of
apoC-I in VLDLs on fasting triglycerides, postprandial
lipemia, and LPL activity in humans. We found that fasting
triglycerides increased linearly with apoC-I enrichment of
VLDLs independent of known regulators of triglycerides
such as apolipoproteins C-II, C-III, and E, apoE genotype,
and traditional cardiovascular risk factors, mainly due to
elevated content of triglycerides per VLDL particle. ApoC-I
enrichment of VLDLs was inversely associated with plasma
LPL activity, but not with LPL mass. Furthermore, the
amount of apoC-I per VLDL particle isolated in the post-
prandial phase was associated with the magnitude of the
postprandial lipemia assessed by total and incremental area
under the triglyceride curve during the postprandial phase.
The impact of apoC-I enrichment of VLDLs on triglyceride
metabolism is probably not reﬂecting a shift in size dis-
tribution of VLDLs towards larger particles since previous
studies have shown that VLDL particles of diﬀerent sizes
(Sf 20–60 and Sf 60–400) had similar amounts of apoC-
Ip e rV L D Lp a r t i c l e[ 21]. Our ﬁndings provide evidence
that normal variations in the content of apoC-I per VLDL
particle had a substantial impact on the triglyceride meta-
bolism, at least partly mediated by inhibition of the LPL
activity.
In agreement with studies in humans [6]a n dm i c e[ 8,
31] with overexpression of the APOC1 gene, we found a
linear increase in serum triglycerides associated with apoC-I
enrichment of VLDLs. The apoC-I encoding gene (APOC1)
is part of the APOE/APOC1/APOC2 gene cluster [32], and
apoC-I has also been shown to mediate some other lipid
modifying eﬀect by interfering with the apoE-mediated
uptake of VLDLs [5, 9]. Thus, it was particularly important
to investigate if the eﬀect was independent of other impor-
tant modulators of triglycerides such as apolipoproteins C-
II and C-III [33, 34] and apoE genotype [35, 36]. The
linear relation between apoC-I enrichment of VLDLs and
fastingtriglyceridesremainedsigniﬁcantafteradjustmentfor
apoC-II and apoC-III, apoE genotype, and even after further
adjustments for traditional cardiovascular risk factors. This
indicates that the enrichment is speciﬁc for apoC-I.
The enhanced levels of fasting triglycerides with increas-
ing apoC-I content in VLDLs was associated with enrich-
ment of VLDL particles by triglycerides, also reﬂecting
increased particle size but no increased number of VLDL
particles (Table 2). Previous studies in mice [8] and humans
[6] with increased expression of apoC-I have also shown
increased content of triglycerides in VLDLs. The mechanism
beyond increased VLDL content of triglycerides may involve
either increased hepatic VLDL-triglyceride production or
an impaired lipolytic processing of VLDLs. Experimental
studies in mice have shown that overexpression of apoC-I
did not inﬂuence the hepatic VLDL-triglyceride production
[8, 37]. Conversely, overexpression of apoC-I prolonged
serum clearance of VLDL-like emulsion particles in vivo
attributed to inhibition of LPL activity by apoC-I [8]. Physi-
ological enrichment of VLDL-like TG emulsions with apoC-
I inhibited the LPL activity by 33% in vitro [8], and VLDL
isolated from apoC-1+/+ m i c eh a da2 8 %d e c r e a s e dL P L -
inducedlipolysiscomparedtoVLDLisolated fromapoC1−/−
mice [1]. Similarly, we observed an inverse relation between
apoC-I enrichment of VLDLs and LPL activity in which
LPL activity decreased by 20% from the lowest to the
highest tertile of apoC-I per VLDL particle. The relation
between apoC-I and LPL may be due to a direct eﬀect on
the speciﬁc activity of LPL since LPL mass was unaltered
across tertiles of apoC-I enrichment of VLDL particles
(Figure 1). However, the molecular mechanism underlying
the association between LPL activity and apoC-I remains to
be elucidated.
The total and incremental area under the postprandial
triglyceride curve showed a linear increase with the amount
of apoC-I molecules per VLDL particle isolated under post-
prandial conditions. Similarly, presence of endogenous
apoC-I (APOC1+/+ APOE−/−)i nm i c eh a ss h o w nm a r k e d
elevation of postprandial triglyceride levels compared to
apoC-I deﬁciency (APOC1−/− APOE−/−) due to increased
hepaticproductionofVLDL-triglyceridesandinhibitedlocal
LPL activity in vivo [1]. However, no such associations were
established among middle-aged men with the apoE3/E3
genotypewithVLDLparticlesisolated3and6hrsafteringes-
tion of the test meal [20]. The apparent discrepancy between
the clinical studies may be due to diﬀerences in age, BMI,
apoE genotype, which are known to inﬂuence postprandial
lipemia [38, 39], and also the time for isolation of VLDL
during the postprandial phase.
In agreement with previous clinical studies [19, 20],
we found a signiﬁcant association between cholesterol and
apoC-I enrichment within VLDL particles isolated both
under fasting and postprandial conditions. In contrast,
human apoC-I-expressing mice deﬁcient of apoE did not
exhibit increased cholesterol levelswithin theVLDL particles
[8]. The molecular mechanism for the association between
cholesterol and apoC-I enrichment of VLDL particles in
humans and the apparent discrepancy between mice and
humans are unknown. However, mice do not express CETP
[40], and its function can therefore not contribute to the
phenotype of APOC1 mice. Even though apoC-I appears
to be a physiological relevant inhibitor of CETP, prolonged
exposure in the circulation of VLDL particles enriched with
apoC-I may facilitate CETP-mediated cholesterol exchange
with HDL, and thereby explaining the relation between
apoC-I and cholesterol enrichment in VLDLs.
The “response-to-retention” hypothesis of atheroscle-
rosis suggested that intimal deposition is proportional to
plasma levels of lipoproteins [41], and Zilversmit proposed
that atherosclerosis was, at least in part, a postprandial
disease due to accumulation of postprandial TRLs in the
circulationandtherebyexposuretothevesselwall[42].More
recent studies have shown eﬃcient penetration and selective
retention of TRLs in sites of lesion formation [43]. Elevated
postprandial levels of TRLs have been associated with both
coronary [44]and carotidartery atherosclerosis[45]. Similar
to previous studies showing a relation between apoC-
I enrichment of VLDLs and early carotid atherosclerosis
[20, 21], we found a higher proportion of subjects with
carotid plaques and greater plaque area among those with8 Journal of Lipids
highest apoC-I content in VLDL. The formation of a more
atherogenic composition with increased cholesterol content
ofVLDLparticles, impaired lipolysisandsubsequentdelayed
clearance rate of VLDLs, and elevated postprandial TRLs
associated with apoC-I enrichment of VLDLs may con-
tribute to the atherosclerotic process. Thus, we suggest that
these speciﬁc modiﬁcation of the triglyceride metabolism
may contribute to the increased risk of atherosclerosis [18,
20, 21]a n dC A D[ 19] associated with apoC-I enrichment of
VLDLs.
In conclusion, the phenotypic expression of apoC-I per
VLDL particles is an important modulator of triglyceride
metabolism in the fasting and postprandial states indepen-
dent of apoC-III and traditional cardiovascular risk factors
and may thereby represent an underlying mechanism for the
association between thecontentof apoC-I per VLDL particle
and carotid atherosclerosis.
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